Quick Answer
Larimar Therapeutics, Inc. reported Research And Development Expense of $154.22 million for the year ending 2025.
- Larimar Therapeutics, Inc. showed an increase of +110.5% in Research And Development Expense from 2024 to 2025.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $1.96 million | Q3 2013: $2.44 million | Q1 2014: $3.28 million | Q2 2014: $4.70 million | Q3 2014: $12.08 million | Q1 2015: $10.22 million | Q2 2015: $12.53 million | Q3 2015: $14.17 million | Q1 2016: $12.50 million | Q2 2016: $10.16 million | Q3 2016: $10.00 million | Q1 2017: $9.68 million | Q2 2017: $10.53 million | Q3 2017: $9.72 million | Q1 2018: $12.43 million | Q2 2018: $12.21 million | Q3 2018: $11.83 million | Q1 2019: $9.63 million | Q2 2019: $3.13 million | Q3 2019: $8.03 million | Q1 2020: $5.01 million | Q2 2020: $8.91 million | Q3 2020: $6.92 million | Q1 2021: $8.97 million | Q2 2021: $9.10 million | Q3 2021: $14.03 million | Q1 2022: $5.81 million | Q2 2022: $5.64 million | Q3 2022: $5.58 million | Q1 2023: $4.56 million | Q2 2023: $5.88 million | Q3 2023: $6.59 million | Q1 2024: $12.94 million | Q2 2024: $19.68 million | Q3 2024: $13.92 million | Q1 2025: $26.55 million | Q2 2025: $23.37 million | Q3 2025: $44.93 million.
- Over the full 14 years of available data (2012 to 2025), Larimar Therapeutics, Inc.'s Research And Development Expense has grown by 1,236.0%.
- Historical annual values: Fiscal year 2025: $154.22 million | Fiscal year 2024: $73.28 million | Fiscal year 2023: $27.67 million | Fiscal year 2022: $24.25 million | Fiscal year 2021: $38.40 million | Fiscal year 2020: $31.41 million | Fiscal year 2019: $20.79 million | Fiscal year 2018: $47.93 million | Fiscal year 2017: $40.84 million | Fiscal year 2016: $39.94 million | Fiscal year 2015: $54.62 million | Fiscal year 2014: $27.39 million | Fiscal year 2013: $9.56 million | Fiscal year 2012: $11.54 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: